Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups

PURPOSE: Assessing impact of poor accrual on premature trial closure requires a relevant metric. We propose defining accrual sufficiency on apparent ability to address primary endpoints (PE) rather than attaining accrual targets. EXPERIMENTAL DESIGN: All phase III trials open January 1, 1993, to Dec...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Schroen, Anneke T., Petroni, Gina R., Wang, Hongkun, Thielen, Monika J., Gray, Robert, Benedetti, Jacqueline, Wang, Xiaofei F., Sargent, Daniel J., Wickerham, Donald L., Cronin, Walter, Djulbegovic, Benjamin, Slingluff, Craig L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3977198/
https://ncbi.nlm.nih.gov/pubmed/21976533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-1633
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados